Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, Emilio Hirsch, Hossein Ardehali, Alessandra Ghigo
Abstract
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
Topics & Concepts
CardiotoxicityAnthracyclineMedicineIntensive care medicineBioinformaticsChemotherapyInternal medicineCancerBreast cancerBiologyChemotherapy-induced cardiotoxicity and mitigationCancer-related cognitive impairment studiesCarbon Nanotubes in Composites